Oragenics 대차 대조표 상태

재무 상태 기준 확인 6/6

Oragenics has a total shareholder equity of $1.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.7M and $1.4M respectively.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$1.35m
주식	US$1.33m
총 부채	US$1.38m
총 자산	US$2.71m

최근 재무 상태 업데이트

Recent updates

재무 상태 분석

단기부채: OGEN's short term assets ($1.6M) exceed its short term liabilities ($1.4M).

장기 부채: OGEN has no long term liabilities.

부채 대 자본 내역 및 분석

부채 수준: OGEN is debt free.

부채 감소: OGEN has no debt compared to 5 years ago when its debt to equity ratio was 0.05%.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: OGEN has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.

예측 현금 활주로: OGEN is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.

Oragenics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Recent updates

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

New major risk - Financial position

First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023)

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

Executive Chairman recently bought US$66k worth of stock

Price target decreased to US$2.25

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Price target increased to US$2.25

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기